Clinical
Monday, February 4, 2019

New momentum for harmonizing TMB results

As more research emerges surrounding the standardization of tumor mutational burden (TMB) assessment, a universal definition of “high TMB” across cancer types does not appear to be feasible.

 

Check out this recent article published in Genes, Chromosomes & Cancer on how QIAGEN is collaborating with leading institutions in cancer research and treatment to harmonize TMB estimation and reporting in clinical samples.

 

Read the full article here!



© QIAGEN 2019. All rights reserved - Trademarks & Disclaimers